Ependymoma Drug Market, by Drug Type (Corticosteroids, Antiseizure Agents and Others), by Disease Type (Subependymoma, Myxopapillary Ependymoma, Anaplastic Ependymoma and Classic Ependymomas), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5332

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Ependymoma Drug Market: Restraint

The major factors that hinder growth of the global ependymoma drug market include side effects associated with the medication. Dexamethasone a corticosteroid used in the treatment of ependymoma causes side effects which include upset stomach, stomach irritation, vomiting, headache, dizziness, insomnia, restlessness, depression, anxiety, acne, increased hair growth, easy bruising etc.

Global Ependymoma Drug Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global ependymoma drug market. Thus, the COVID-19 pandemic is expected to have a negative impact on supply chain of ependymoma drug market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review Journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.